source
- Oruka’s experimental psoriasis drug achieves near-complete skin clearance in Phase 2 trialOruka Therapeutics reported that its experimental IL-23 inhibitor ORKA-001 cleared the skin of 40 of 63 patients (about 63%) in a Phase 2 study, achieving a PASI 100 response at 16 weeks. A further…
- Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitorEli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…